Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 60 recruiting now later-stage tilt #46 of 28,707 conditions

Atrial Fibrillation: later-stage trial registry

60 of 204 indexed Atrial Fibrillation trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #46 of 28,707 conditions by registered trial count.

204 US clinical trials · 60 currently recruiting · #46 of 28,707 conditions by registered trial count

Atrial Fibrillation: 204 US clinical trials tracked, 60 recruiting.

Atrial Fibrillation is the subject of 204 registered US clinical trials on ClinicalTrials.gov, 60 of them currently open to new participants. 45 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is The Cleveland Clinic, running 9 of these trials.

Enrollment posture brief

Registry condition atrial-fibrillation

OPEN 60 | RECR 29% | LATE 45 | EARLY 19 | RANK #46 | SPON 9

Nearest open-share peer: Addiction (29% recruiting · 17 trials)

Spinal Cord Injuries53.2%Mild Cognitive Impairment48.5%Dementia39.1%Glioblastoma39%Atrial Fibrillation (this)29%
Open-enrollment share among volume-matched conditions near Atrial Fibrillation

Atrial Fibrillation lists 60 open slots (29% of 204 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Atrial Fibrillation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Atrial Fibrillation is recruiting below its size-band peers.

    60 of 204 indexed trials (29.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Atrial Fibrillation trials is spread across many organizations.

    The Cleveland Clinic accounts for 9 of 204 trials (4.4%). 109 distinct sponsors appear on at least one study for this condition label.

  3. Typical Atrial Fibrillation enrolment sits around 200 participants.

    Median target enrolment is 200 among the 203 trials that report a genuine target (sentinel values excluded). 59 of those (29.1%) plan for fewer than 100 participants.

  4. Atrial Fibrillation splits between interventional and observational designs.

    137 interventional and 67 observational studies make up this index (67.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 212Phase 326Phase 419

Open and recent trials

204 total, page 4 of 5

COMPLETED 150 participants

Is Endothelial Function a Predictor of Successful Ablation Therapy Provided to Patients With Atrial Fibrillation?

Itamar-Medical, Israel

NCT02129842

COMPLETED 142 participants

First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data

Boston Scientific Corporation

NCT01161589

COMPLETED Phase 2 134 participants

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

Gilead Sciences

NCT01522651

COMPLETED 130 participants

Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation

Beth Israel Deaconess Medical Center

NCT02332096

COMPLETED Phase 1 130 participants

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

Joseph Mathew, M.D.

NCT02498769

COMPLETED NA 129 participants

Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation - EASY AF STUDY

S4 Medical

NCT04659213

COMPLETED 118 participants

Short Term Outcomes From Minimally Invasive Surgery for the Treatment of Atrial Fibrillation

Virginia Commonwealth University

NCT00571597

COMPLETED Phase 4 117 participants

Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

University of Michigan

NCT04625946

COMPLETED Phase 4 101 participants

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

Vanderbilt University Medical Center

NCT01976507

COMPLETED NA 100 participants

General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation

Virginia Commonwealth University

NCT02896595

COMPLETED Phase 4 100 participants

The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock

Mayo Clinic

NCT00787800

COMPLETED Phase 1 95 participants

Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study

EP MedSystems

NCT00281073

COMPLETED Phase 4 86 participants

Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation

Biosense Webster

NCT00926783

COMPLETED 85 participants

Peri-device Leakage Closure After LAAO

Cardiovascular Center Frankfurt

NCT04590898

COMPLETED NA 84 participants

Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation

Dhanunjaya Lakkireddy, MD, FACC

NCT00798356

COMPLETED NA 84 participants

Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF

Stanford University

NCT02456233

COMPLETED NA 81 participants

Continued Access Protocol

Medtronic Cardiac Rhythm and Heart Failure

NCT00889681

COMPLETED Phase 4 80 participants

Prevention of Atrial Fibrillation Following Esophagectomy

Indiana University

NCT00420017

COMPLETED NA 78 participants

Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps

Virginia Commonwealth University

NCT01581437

COMPLETED Phase 3 75 participants

Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent

Medtronic Cardiac Surgery

NCT00506493

COMPLETED 72 participants

Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography

Elad Anter

NCT02213666

COMPLETED NA 71 participants

Cardiac Resynchronization Therapy Efficacy Enhancements

Medtronic Cardiac Rhythm and Heart Failure

NCT02222818

COMPLETED NA 70 participants

Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation

University of Cincinnati

NCT02524977

COMPLETED 68 participants

Implantable Loop Recorders in Post-atrial Fibrillation (AF) Ablation: RPAF-A

The Cleveland Clinic

NCT01061125

COMPLETED NA 64 participants

The Physiological Effects of Pacing on Catheter Ablation Procedures to Treat Atrial Fibrillation

NYU Langone Health

NCT02766712

COMPLETED Phase 4 63 participants

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Boehringer Ingelheim

NCT01896297

COMPLETED NA 61 participants

Patient Centered Mobile Health Technology Enabled Atrial Fibrillation Management

Johns Hopkins University

NCT05400837

COMPLETED 60 participants

Post-Market Surveillance With a Novel mHealth Platform

Yale University

NCT03436082

COMPLETED Phase 2 60 participants

Combined Treatment of Arterial Hypertension and Atrial Fibrillation

Meshalkin Research Institute of Pathology of Circulation

NCT01897545

COMPLETED NA 55 participants

Esophageal Cooling for AF Ablation

University of Pennsylvania

NCT03691571

COMPLETED 52 participants

ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1

Duke University

NCT02569528

COMPLETED 50 participants

OptiSense™ Performance in Detecting Atrial Episodes

Abbott Medical Devices

NCT00870324

COMPLETED NA 50 participants

Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation

Vivek Reddy

NCT01635998

COMPLETED NA 42 participants

Esophageal Temperature Management During Cryo AF Ablation (EnsoETM)

Northwestern University

NCT04079634

COMPLETED 42 participants

Safety Monitoring of Patients Having Pulmonary Vein Ablation

The Cleveland Clinic

NCT00590668

COMPLETED 39 participants

FREEZE-AFIB Post-Market Study

AtriCure

NCT05089877

COMPLETED 37 participants

Comparison of Rotational Angiography/Electroanatomical Mapping Fusion Versus CT/Electroanatomical Mapping Fusion to Guide AF Ablation

Steward St. Elizabeth's Medical Center of Boston

NCT01537237

COMPLETED NA 35 participants

Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial

University of Pennsylvania

NCT03646643

COMPLETED NA 32 participants

One More Magnetic Resonance Imaging

Saint Luke's Health System

NCT02293070

COMPLETED NA 25 participants

Atrial Fibrillation Recurrence in Sleep Apnea

Mayo Clinic

NCT00263757

COMPLETED 25 participants

AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

Ablacon

NCT05481359

COMPLETED Phase 1 24 participants

Effect of Diltiazem on Pharmacokinetics of BMS-914392

Bristol-Myers Squibb

NCT01211808

COMPLETED 21 participants

Relationship Between Autonomic Central Nervous System Activation and Atrial Fibrillation Using Functional MRI (fMRI)

University of Utah

NCT02524028

COMPLETED 21 participants

Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

Abramson Cancer Center at Penn Medicine

NCT04118530

COMPLETED NA 17 participants

Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias

Apple

NCT03769207

COMPLETED NA 17 participants

ArcticLine Feasibility Study

Medtronic Cardiac Ablation Solutions

NCT03604263

COMPLETED 16 participants

Siemens 3-D C-Arm CT of the Heart Chambers

The Cleveland Clinic

NCT00619450

COMPLETED Phase 1 13 participants

Stroke Feasibility Study

AtriCure

NCT01997905

COMPLETED NA 13 participants

Transatrial Pericardial Separation to Enhance Safety of Subxiphoid Pericardial Access for Left Atrial Appendage Ligation

Henry Ford Health System

NCT06584370

COMPLETED NA 10 participants

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

Jeffrey Goldberger

NCT03082963

← Previous Page 4 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 12
Phase 3 26
Phase 4 19

Named interventions

Most-linked intervention names on Atrial Fibrillation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
13 trials
placebo Drug
5 trials
Apixaban Drug
4 trials
Rivaroxaban (Xarelto, BAY59-7939) Drug
3 trials
AliveCor Device
2 trials
amiodarone Drug
2 trials
Azimilide Dihydrochloride Drug
2 trials
dronedarone (SR33589) Drug
2 trials

US sites by state

Facility locations filed on Atrial Fibrillation trials. A trial with sites in several states counts in each.

California 47 trials
Florida 45 trials
New York 34 trials
Ohio 32 trials
Arizona 28 trials
Massachusetts 27 trials
Texas 26 trials
Illinois 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Atrial Fibrillation page

204 registered trials, 60 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atrial Fibrillation condition card totals 204 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.